<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228150</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5287</org_study_id>
    <nct_id>NCT00228150</nct_id>
  </id_info>
  <brief_title>Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease</brief_title>
  <official_title>A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the&#xD;
      progression of Parkinson symptoms in patients with early PD. The primary outcome will be the&#xD;
      time to progression of disability warranting initiation of L-dopa or a dopamine agonist.&#xD;
      Secondary outcomes will comprise assessments of symptoms, activities of daily living and&#xD;
      global clinical status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multinational, multicenter, randomized, parallel-group, double-blind, phase II study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disability warranting introduction of Ldopaor a dopamine agonist.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
  </secondary_outcome>
  <enrollment type="Actual">564</enrollment>
  <condition>Parkinson Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR57667B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female outpatients.&#xD;
&#xD;
          -  Age &gt;=35 years at screening.·&#xD;
&#xD;
          -  Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's&#xD;
             symptoms, i.e. resting tremor, bradykinesia and rigidity.&#xD;
&#xD;
          -  Duration of the disease of less than 3 years since diagnosis·&#xD;
&#xD;
          -  Modified Hoehn and Yahr stage &lt;= 2.5.&#xD;
&#xD;
          -  Untreated patients.&#xD;
&#xD;
          -  Generally healthy and ambulatory.&#xD;
&#xD;
          -  Patient has given his informed written consent and is capable of following study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any indication of forms of parkinsonism other than PD.&#xD;
&#xD;
          -  Severe resting tremor.&#xD;
&#xD;
          -  Presence of either dyskinesia, fluctuations, or loss of postural reflexes·&#xD;
&#xD;
          -  Treatment with L-Dopa, dopamine agonist, amantadine, anticholinergics,&#xD;
             catechol-o-methyltransferase (COMT ) inhibitors, selegiline, dopamine receptor&#xD;
             antagonists, catecholamine depleters, indirect dopamine agonists or alphamethyldopa.&#xD;
&#xD;
          -  Electroconvulsive therapy (ECT).&#xD;
&#xD;
          -  Use of CYP3A4 strong, and moderate inducers or inhibitors.&#xD;
&#xD;
          -  Participation in another clinical trial with an investigational drug within two months&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Dementia, uncontrolled depression, psychotic disorder.&#xD;
&#xD;
          -  History of substance-related disorders including alcohol or other substance use&#xD;
             disorders.&#xD;
&#xD;
          -  Females of child bearing potential.&#xD;
&#xD;
          -  Evidence (detected by history, physical examination and/or laboratory/ECG tests) of&#xD;
             any clinically significant or unstable medical disorder that could interfere with the&#xD;
             patient's participation in the clinical trial; interfere with the absorption,&#xD;
             metabolism or excretion of the study medication; or interfere with the evaluation of&#xD;
             the study drug.&#xD;
&#xD;
          -  Alterations of laboratory tests or ECG findings of potential clinical significance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark GUTMAN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Werner POEWE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier RASCOL, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo TOLOSA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Advisory Committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Megrine</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guilford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Morocco</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>December 22, 2008</last_update_submitted>
  <last_update_submitted_qc>December 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>levodopa</keyword>
  <keyword>dopamine agonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

